Patents by Inventor Pascal A. Stein

Pascal A. Stein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody Fusion Proteins with a Modified FcRn Binding Site
    Publication number: 20150274797
    Abstract: Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.
    Type: Application
    Filed: October 28, 2014
    Publication date: October 1, 2015
    Inventors: Kin-Ming Lo, Pascal A. Stein
  • Antibody fusion proteins with a modified FcRn binding site
    Patent number: 8907066
    Abstract: Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Kin-Ming Lo, Pascal A. Stein
  • Nucleic acids encoding interleukin-12P40 variants with improved stability
    Patent number: 8188248
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Grant
    Filed: December 7, 2010
    Date of Patent: May 29, 2012
    Assignee: Merck Patent GmbH
    Inventors: Gordon D. Webster, Suzanne P. McKenzie, Kin-Ming Lo, Pascal A. Stein
  • Antibody Fusion Proteins with a Modified FcRn Binding Site
    Publication number: 20100272720
    Abstract: Disclosed are antibody fusion proteins with a modified FcRn binding site and nucleic acid molecules encoding them. The antibody fusion protein include two polypeptide chains, wherein the first polypeptide chain includes a biologically active molecule linked to at least a portion of an immunoglobulin constant region. The second polypeptide chain includes at least a portion of an immunoglobulin constant region. One of the polypeptide chains includes a mutation in the FcRn binding site that reduces binding to FcRn. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins for treating diseases and conditions alleviated by the administration of the fusion proteins.
    Type: Application
    Filed: April 20, 2010
    Publication date: October 28, 2010
    Applicant: Merck Patent GmbH
    Inventors: Kin-Ming Lo, Pascal A. Stein
  • IL-2 FUSION PROTEINS WITH MODULATED SELECTIVITY
    Publication number: 20090098609
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Application
    Filed: December 1, 2008
    Publication date: April 16, 2009
    Applicant: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Pascal A. Stein, Kin-Ming Lo
  • Cancer treatments including administering IL-2 fusion proteins with modulated selectivity
    Patent number: 7462350
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: December 9, 2008
    Assignee: EMD Serono Research Center, Inc.
    Inventors: Stephen D. Gillies, Pascal A. Stein, Kin-Ming Lo
  • IL-2 fusion proteins with modulated selectivity
    Patent number: 7186804
    Abstract: The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are able to bind to more than one type of cytokine receptor expressed on cells and also bind to more than one cell type. In addition, the fusion proteins of the invention exhibit a longer circulating half-life in a patient's body than the corresponding naturally occurring cytokine.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: March 6, 2007
    Assignee: EMD Lexigen Research Center Corp.
    Inventors: Stephen D. Gillies, Pascal A. Stein, Kin-Ming Lo